Company intelligence

Tarsier Pharma

BiotechActive

Is this your company? Get featured or correct your listing →

Suggest a correction

We're still building this profile — here is what Pulse has covered.

Latest Pulse

  1. Biotech's IPO Window: Open, But Only for the Strongest PipelinesTarsier Pharma's ~$45 million NYSE American debut shows biotech's IPO window remains open in 2026 -- but only for companies with genuinely differentiated, late-stage pipelines, not broad speculative interest.→

Coverage Timeline

newest first
  1. Jul 13, 2026IPOBiotech's IPO Window: Open, But Only for the Strongest Pipelines$45M target→

All Coverage

IPO

Biotech's IPO Window: Open, But Only for the Strongest Pipelines

Illustration for: Biotech's IPO Window: Open, But Only for the Strongest Pipelines
IPO$45M target

Biotech's IPO Window: Open, But Only for the Strongest Pipelines

Tarsier Pharma's ~$45 million NYSE American debut shows biotech's IPO window remains open in 2026 -- but only for companies with genuinely differentiated, late-stage pipelines, not broad speculative interest.

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly